Prostanoids, ornithine decarboxylase, and polyamines in primary chemoprevention of familial adenomatous polyposis

• Published in: Gastroenterology (New York, N.Y. 1943) Vol. 126; no. 2; p. 425
• Main Authors: Giardiello, Francis M, Casero, Jr, Robert A, Hamilton, Stanley R, Hylind, Linda M, Trimbath, Jill D, Geiman, Deborah E, Judge, Katharine R, Hubbard, Walter, Offerhaus, G Johan A, Yang, Vincent W
• Format: Journal Article
• Language: English
• Published: United States 01.02.2004
• Subjects: Adenomatous Polyposis Coli - diagnosis; Adenomatous Polyposis Coli - genetics; Adenomatous Polyposis Coli - metabolism; Adenomatous Polyposis Coli - prevention & control; Colon - metabolism; Cyclooxygenase Inhibitors - therapeutic use; Double-Blind Method; Genotype; Humans; Intestinal Mucosa - metabolism; Ornithine Decarboxylase - metabolism; Phenotype; Polyamines - metabolism; Prostaglandins - metabolism; Sulindac - therapeutic use; Treatment Failure

Familial adenomatous polyposis because of germline mutation of the adenomatous polyposis coli gene is characterized by development of colorectal adenomas and, ultimately, colorectal cancer. The usefulness of colorectal mucosal compounds to predict the effect on adenoma development of primary chemopr...